November 3, 2019 2:45pm
Fate Therapeutics (FATE), Vericel (VCEL), Regenxbio (RGNX) and Ultragenyx (RARE) on 11/5;
AxoGen (AXGN), Athersys (ATHX), Ionis Pharmaceuticals (IONS), Sangamo Therapeutics (SGMO), Voyager Therapeutics (VYGR), Bellicum Pharmaceuticals (BLCM) and Caladrius Biosciences (CLBS) on 11/6;
Adverum Biotechnologies (ADVM), Audentes Therapeutics (BOLD) and Cellectis (CLLS) and Stemline Therapeutics (STML) on 11/7
…. and Biostage (BSTG) , BioLife Solutions (BLFS), and Applied Genetic Technologies (AGTC) on 10/12
Be ready … SELL the highs, wait for new bottoms or just HOLD for the temporary slide!
Look for guidance to the short and near-term future and the ability to “TRUST” the CEO as well as a strong “runway” but, be on the outlook for those who anticipate … accessing the capital markets.
Its’s dangerous to be so fragile until NEXT YEAR 2020 with current share pricing!
It’s reality training and re-education time!